

**Eksemlforeningen**

Hvidovrevej 108 , 2650 Hvidovre, Denmark  
anne@vastrup.dk  
("Patient Group")

Represented by Ms. Anne Vastrup  
("MS. VASTRUP" or "you")

August 13, 2025

**PATIENT GROUP AGREEMENT**  
*Patient Expert Consultancy*

Dear MS. VASTRUP,

This letter is a legal agreement (**Agreement**) that sets out the terms on which **F. Hoffmann-La Roche Ltd** of Grenzacherstrasse 124, CH 4070 Basel, Switzerland (**we** or **Roche**) would like to engage you, as an expert in Patient Advocacy, to perform the activity described overleaf (**Activity**).

It comprises of a description of the Activity, the Terms of Engagement (**Terms**), and the **Privacy Notice**.

**Signing this Agreement means that Patient Group and MS. VASTRUP agree to the following:**

1. This Agreement commences on the date of last signature of this Agreement (**Effective Date**) and will last for a period of two (2) years unless terminated earlier. For any Statement of Work, the term of this Agreement is extended until completion of the Further Activity under that Statement of Work. Patient Group and Roche are the **parties** to this Agreement.
2. **MS. VASTRUP performs the Activity from the Effective Date (but not sooner) in accordance with the Terms.** Roche is not obliged to pay for any work (including pre-work) performed before the Effective Date.

If there are any Terms you do not understand, please get in touch with your Roche Contact (their details are in the description of the Activity).

## *The Activity*

<b>Objective &amp; Description</b>	<p>The purpose of the Activity is to:</p> <ul style="list-style-type: none"> <li>• Discuss patient insights to inform patient journey development and clinical development &amp; evidence-generation plan,</li> <li>• Provide insights on potential gaps and solutions from patient perspective living with the condition,</li> <li>• Provide advice to be used to further develop/strengthen evidence generation &amp; development plan: <ul style="list-style-type: none"> <li>○ Provide input on current clinical trial program &amp; studies, identified gaps and unmet needs within patient journey &amp; plan from pediatric point of view,</li> <li>○ Provide advice on clinical trial patient experience improvement,</li> </ul> </li> <li>• Discuss on current landscape in AD and advice on strengthening current evidence plan and insights,</li> <li>• Strategically advise on what the company can do to transform healthcare in the interest of patient.</li> </ul> <p>Your role: Consultant</p>
------------------------------------	--

<b>Dates &amp; Times</b>	<b>Start Date</b>	August 25, 2025	<b>End Date</b>	December 31, 2025
--------------------------	-------------------	-----------------	-----------------	-------------------

<b>Venue</b>	Virtual
--------------	---------

<b>Fee</b>	<p>We will pay Patient Group a total fee of <b>20,800.00 DKK</b>, which is made up of:</p> <p><b>Preparation time:</b> 3 hours;</p> <p><b>Activity time:</b> 12 hours (1 hour interview, 4 hours focus group meeting, 7 hours consultancy (document reviews, ICF and Protocol reviews, ad-hoc meetings etc.));</p> <p><b>Post activity time:</b> 1 hour;</p> <p><b>Each multiplied by an hourly rate of:</b> 1,300.00 DKK, per hour;</p>
------------	--

Roche needs to approve any additional time spent on the Activity in advance.

Roche will only compensate for the hours worked.

To receive this payment, you have to do the following, once the Agreement (or any Statement of Work) is signed:

- Perform the Activity (or any Further Activity) as agreed;
- Obtain an invoice template from Roche contact person which references the appropriate Roche purchase order number;
- Complete and sign the invoice and submit with accompanying proof of expenses (if applicable), immediately, but no later than 30 days, after receipt of invoice from Roche;
- Send invoice to Accounts Payable at  
F. Hoffmann-La Roche Ltd  
Accounts Payable  
Grenzacherstrasse 124  
CH-4070 Basel, Switzerland

Or a scanned version (PDF) of the signed invoice with receipts (if any) can be sent by email to [glo.global-pp-contracts@roche.com](mailto:glo.global-pp-contracts@roche.com)

Roche will pay the invoice upon receipt of the invoice and Patient Group's banking details, but no later than 30 days upon receipt.

---

**Your Roche Contact** Asla Kodzhaibrahimoglu  
Global Patient Partnership Leader  
+41 79 502 04 96  
[asla.kodzhaibrahimoglu@roche.com](mailto:asla.kodzhaibrahimoglu@roche.com)

---

**Further Activity** Roche may ask you to perform further activities in addition to the Activity, during the term of this Agreement ("Further Activity"), as stated in one or more Statements of Work ("Statement of Work"), Each Statement of Work will include the terms of this Agreement and will become a part of this Agreement. For any Further Activity, each Statement of Work will identify compensation for such Further Activity. Parties are neither required nor obliged to offer or provide any Further Activity (or any minimum number of Further Activities).

**This space is intentionally left blank.**

## *Terms and conditions*

1. **Roche Policies & Independence.** Patient Group recognizes that it is Roche's policy to comply with all applicable laws, regulations, industry codes, permits and consent orders and to act in a proper and ethical manner. We are not asking Patient Group and MS. VASTRUP to participate in the Activity with any intention to induce, influence or reward prescribing, supply, administration, recommendation, buying or selling of any of our products or services. We expect you to continue exercising your independent judgement. MS. VASTRUP's status with Roche will be at all times during the term of this Agreement that of an independent contractor and MS. VASTRUP will not hold himself/herself out as our employee, worker, agent or partner. Patient Group and MS. VASTRUP warrant and represent that no conflict of interest with any party and/or parties exist by entering into this Agreement. No party will have the authority to bind or obligate another party to this Agreement in any matter without that other party's written approval. Nothing in this Agreement will be construed to give MS. VASTRUP the power or authority to be an agent of, or to act or make representations for Roche.
2. **Fee and Expenses.** Any Fee specified in the description of the Activity is the sole remuneration for the Activity, and represents fair market value. We will pay for any travel and accommodation costs specified in the description of the Activity. We will also reimburse reasonable expenses actually incurred by MS. VASTRUP in performance of the Activity, provided they are pre-approved by your Roche Contact in writing, submitted within 30 days of completion of the Activity and accompanied by receipts. Except for VAT or equivalent taxes, the amounts payable by us under this Agreement are inclusive of all taxes and duties; Patient Group is responsible for its own tax affairs. We will transfer all monies into Patient Group's account only.
3. **Confidentiality.** Subject to clause 4 (Transparency), the term of this agreement and for the next ten (10) years, Patient Group and MS. VASTRUP will keep strictly confidential all information received from Roche, whether related to or obtained in connection with the Activity or any Further Activity, and whether or not recorded in any way, that is not in the public domain, (incl. information about this Agreement, our research interests, the results of our research, our product development and other commercial activities), which Patient Group or MS. VASTRUP either (a) first receive from us or one of our affiliates, or (b) create themselves in the course of the Activity. We ask that Patient Group and MS. VASTRUP do not disclose this information to anyone without our prior written approval (unless required by law or court to do so), and not use it, except in the performance of the Activity. In the case that it has been agreed otherwise in writing, both parties shall make reasonable efforts to mark their documents and data as confidential. We may ask Patient Group/you to return to us all documents and other materials incorporating this information.
4. **Transparency.** Patient Group and MS. VASTRUP understand that we are committed to full transparency and that we may disclose any information relating to this Agreement. Patient Group and MS. VASTRUP (as applicable) warrant and represent to comply with any laws, regulations or rules of professional conduct applicable to Patient Group and MS. VASTRUP that oblige Patient Group and MS. VASTRUP to disclose or report any transfers of value provided under this Agreement.
5. **Data and Results.** All data and results (including but not limited to copyrights) which come from or are generated by Patient Group and MS. VASTRUP for Roche under this Agreement will become the exclusive property of Roche. Any use of these data and results by Roche or Roche's designee does not entitle Patient Group and MS. VASTRUP to any additional payment under this Agreement. Should any inventions and/or improvements result from the Activity (or any Further Activity) performed under this Agreement (or any Statement of Work), Roche will be entitled, without any additional payment to Patient Group and MS. VASTRUP, to file in its own name relevant patent applications, and the inventions and improvements will become and remain the property of Roche.
6. **Publicity.** Patient Group and MS. VASTRUP must not use Roche's name, trademark or any Roche product brand names in any materials or public statements (including social media) Patient Group and MS. VASTRUP may wish to make in relation to the Activity. If Patient Group or MS. VASTRUP wishes to do this, Roche's prior written approval must be requested.
7. **Liability.** Each party shall be liable for any and all losses, reasonable costs (including attorney fees), damages (collectively "Damages") arising out of or resulting from its own negligence or wilful misconduct relating to its performance under this Agreement. The party's total liability shall be limited to three (3) times of the value of this agreement. The limitation of liability hereunder shall not apply for (i) claims for fraud, wilful misconduct, gross negligence, and/or (ii) claims arising from a breach of confidentiality obligations and/or (iii) claims arising from a breach of intellectual property rights and/or (iv) third party claims.  
Patient Group agrees to secure and maintain adequate insurance of comprehensive general liability. Upon request, Patient Group shall forward to Roche a certificate evidencing such insurance (or an according letter of self-insurance).
8. **Termination.** Either party may terminate this Agreement or Statement of Work, with or without reason, by providing written notice. If either party violates any of the material terms and conditions of this Agreement or any Statement of Work, the other party may terminate this Agreement or that Statement of Work immediately by giving written notice to the violating party. Clauses 4-8, Clause 11 and the Privacy Notice will survive termination or expiry of this Agreement.
9. **Miscellaneous.** This Agreement is the entire agreement in relation to its subject matter, and supersedes all prior oral or written agreements, between both parties. Except for changes in venue, location or time of the event, no amendments, changes, modifications or alterations of the terms and conditions of this Agreement will be binding upon any party unless in writing and signed by all parties.
10. **E-Signatures.** The parties agree that signing this Agreement (or a Statement of Work) by e-Signatures (as defined below) will have the same legal force and effect as the exchange of original signatures.  
Pursuant to this Agreement, e-Signatures will mean a signature that consists of one or more letters, characters, numbers or other symbols in digital form incorporated in, attached to or associated with the electronic document, that (a) is unique to the person making the signature; (b) the technology or process used to make the signature is under the sole control of the person making the signature; (c) the technology or process can be used to identify the person using the technology or process; and (d) the electronic signature can be linked with an electronic document in such a way that it can be used to determine whether the electronic document has been changed since the electronic signature was incorporated in, attached to or associated with the electronic document.
11. **Governing Law & Jurisdiction.** This Agreement is governed by Swiss law and subject to the exclusive jurisdiction of the courts of Basel-city Switzerland.

If you sign this Agreement, you: (1) confirm that you have read and understood the Privacy Notice, and (2) agree to perform the Activity and comply with the Terms.

Yours faithfully

I understand and agree with the contents of this Agreement.

**SIGNED** for and on behalf of  
**F. Hoffmann-La Roche Ltd**

**SIGNED** for and on behalf of  
**Eksempforeningen**

Signed by:

*Asla Kodzhaibrahimoglu*

.....92XD12D3X9744XB.....  
Signature

Signed by:

*Anne Skov Vastrup*

.....5ADF358E642D4BA.....  
Signature

Asla Kodzhaibrahimoglu

Anne Skov Vastrup

.....  
Name

.....  
Name

Global Patient Partnership Leader

14-aug-2025

.....  
Position

.....  
Date

17-Aug-2025

.....  
Date

**Read and acknowledged (including Appendix 1 "Privacy Notice"):**

Signed by:

*Mai-Lise Nguyen*

.....F4D8D226811F4B4.....  
Signature

Signed by:

*Anne Skov Vastrup*

.....5ADF358E642D4BA.....  
Signature

Mai-Lise Nguyen

Anne Skov Vastrup

.....  
Name

.....  
Name of Representative/Participant

Global Patient Partnership Group Leader

14-aug-2025

.....  
Position

.....  
Date

17-Aug-2025

.....  
Date

## *Privacy Notice*

1. **This Privacy Notice** tells you how we process your Personal Data. **Personal Data** is any information processed under this Agreement that identifies, or that, together or in connection with other information, can be uniquely linked to an individual. Any operation performed on Personal Data, including the use, collection, structuring, storage, adaptation, consultation, disclosure, dissemination or otherwise making available, or erasure is **processing**.
2. **What data we process and why:** You acknowledge that F. Hoffmann-La Roche Ltd, of Grenzacherstrasse 124, CH 4070 Basel, Switzerland (the **controller**, or **we**), or our affiliates or vendors acting on our behalf, may, in the performance of this Agreement, process your Personal Data (**Your Data**) for the purposes (**Permitted Purposes**) and on the basis set out in the table below.

<i>Your Data</i>	<i>Permitted Purposes</i>	<i>Legal basis under the GDPR</i>
Name and contact details Details of this Agreement	For performance of your and our obligations under this Agreement*	Performance of a contract to which you are a party (Article 6(1)(b) GDPR)
Bank details Value of any Fee and expenses	For compliance with applicable EU and Member State laws*	Compliance with a legal obligation to which we are subject (Article 6(1)(c) GDPR)
Details of Suspected Adverse Reactions, Special Situations and product complaints	For compliance with applicable EU and Member State laws*	Compliance with a legal obligation to which we are subject Processing is necessary for reasons of public interest in the area of public health, so as to ensure high standards of quality and safety of health care and of medicinal products or medical devices (Article 6(1)(c) and Article 9(2)(i) GDPR)
Information concerning health or disease or condition	For our internal educational and information purposes, including in internal presentations and communications	Your (or if you are a carer, patient's) consent, which we will seek on a separate form. (Article 6(1)(a) and Article 9(2)(a) GDPR) If you have provided consent for the processing of Your Data you have the right to withdraw that consent at any time, which will not affect the lawfulness of the processing before your consent was withdrawn.
Name and contact details Details of this Agreement Value of any Fee and expenses Photographs, film or audio recordings of yourself (see description of the Activity)	For our and our affiliates' commercialization activities (including external or internal publications and social media)	Our legitimate interests in placing and advertising our products on the market. (Article 6(1)(f) GDPR)

*\*If you do not provide personal data that is necessary for this purpose, we may not be able to comply with our contractual or legal obligations and will tell you about the implications, which will include the termination of this Agreement.*

3. **Data sources.** We obtain Your Data from this Agreement, you directly, our internal and publicly available sources.
4. **Recipients of Your Data and how we share Your Data.** We may share Your Data with our affiliates around the world. Our affiliates will use Your Data for the same purpose as we do. A list of our affiliates is available in the current annual report, which can be found in the Investors section of [www.roche.com](http://www.roche.com). We may also share Your Data with third parties, e.g. travel agencies for the purposes described above. Therefore, Your Data may be transferred to or stored in a geographic region that imposes different privacy obligations your country of origin. This means that Your Data may be sent to a country with less restrictive data protection laws than your own. Any such transfer will be conducted in compliance with applicable law. However, we will still ensure that Your Data is processed only for Permitted Purposes and in accordance with our policies and data protection laws that apply to Your Data. If your Personal Data is covered by the GDPR and, where appropriate, we may rely on European Commission adequacy decisions about certain countries, as applicable. Safeguard measures for transfers of Your Data outside the EEA, which we may rely on from time to time include having standard clauses approved by the European Commission in our contracts, using Binding Corporate Rules, approved Codes of Conduct, Certifications or, in exceptional circumstances, permissible statutory derogations using other acceptable data transfer mechanisms. You can learn more about the safeguards we use to transfer Your Data by contacting us using the information provided below.
5. **How long we keep Your Data.** Your Data will be processed and stored by us (or on our behalf) for as long as is necessary to fulfil the purposes of this Agreement or to comply with our or our affiliates' legal obligations or requirements of any applicable code of practice.
6. **Automated decision-making.** Our processing of Your Data will not involve automated decision-making.

7. **Your Rights.** You have the right to know about, access and receive a copy, rectify, request deletion, restrict or object to the processing (including direct marketing) of, Your Data, and to data portability (i.e., receive Your Data in a standardised format so you can transfer it to another controller) to the extent permitted by applicable laws. You can exercise these rights and ask questions about the processing of Your Data by contacting us using the information provided below. You also have the right to make a complaint to the competent supervisory authority about the processing of Your Data.
8. **Identify and contact details of the data controller.** The data controller is F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland. In the event that Your Data is covered by the EU General Data Protection Regulation (“EU”) 2016/679 (“GDPR”), the EU representative of F. Hoffmann-La Roche Ltd is Roche Privacy GmbH, Emil-Barell-Str. 1, D-79639 Grenzach-Wyhlen. You may contact the data controller by mail at Grenzacherstrasse 124, CH-4070 Basel, Switzerland or email at [global.privacy@roche.com](mailto:global.privacy@roche.com)

**This space is intentionally left blank.**